web analytics
21.7 C
Munich
Tuesday, August 3, 2021

ImmCelz, CaverStem, StemSpine; the Run on Creative Medical Technology Holdings Inc (OTCMKTS: CELZ)

Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) is making a powerful move up after the Company announced novel data and patent filing No. 63131261 describing the ability of ImmCelz® to reverse liver failure in the carbon tetrachloride preclinical model of hepatocyte necrosis.  These findings are the basis for a patent filing covering various means of generating the ImmCelz® product in a specific manner.

CELZ has skyrocketed from well under a penny trading over $10 million in dollar volume today and is quickly attracting legions of new shareholders who see big things happening here. CELZ flagship CaverStem has the only procedure to treat Erectile Dysfunction with adult stem cells in the US. Microcapdaily has reported on CELZ for years stating sometime in 2018: “CELZ has runner in its blood and a long history of huge moves skyrocketing from $0.002 in March of last year to highs topping $0.07 per share in August, CELZ loves to run and is a volume leader regularly among the top most traded on the OTCBB.”

Creative Medical Technology Holdings Inc (OTCMKTS: CELZ) is a commercial stage biotechnology company committed to improving patient lives in the areas of Urology, Neurology and Orthopedics. For years the Company has been focused on regenerative medical solutions for unmet Urological, Neurological and Orthopedic needs. CELZ has developed an extensive intellectual property portfolio utilizing stem cells for the treatment of multiple indications and commercialized complete patented and trademarked protocols for erectile dysfunction under the CaverStem® brand and the FemCelz® brand for the treatment of female sexual dysfunction. The Company’s StemSpine® technology will be launched in the near future. CELZ is also breaking new ground with its AmnioStem™ technology for the treatment of strokes, utilizing our patented amniotic fluid-based stem cell. The Company’s “science-first” approach to procedures ensures that all of its technology is proven to be both safe and effective.

Since acquiring its groundbreaking stem cell (Amniostem), Creative Medical has developed proprietary protocols, built an extensive intellectual property portfolio, developed complete treatment offerings for erectile dysfunction, launched a 40-patient trial for ED at UCLA and are breaking new ground for treating stroke using our newly acquired amniotic fluid-based stem cell.  The CELZ team consists of leading international physicians and scientists specializing in regenerative medicine. CELZ has a valuable intellectual property portfolio including 14 patents and applications and 4 trademarks as well as 2 patented cell therapies now in market for 2019 (caverstem and FemCelz. StemSpine is also launching soon)

Creative Medical Technology Holdings (CELZ.OTC) stem cell research puts rheumatoid arthritis in its crosshairs | Equity.Guru

To Find out the inside Scoop on CELZ Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CELZ

On December 29 CELZ reported novel data and patent filing No. 63131261 describing the ability of ImmCelz® to reverse liver failure in the carbon tetrachloride preclinical model of hepatocyte necrosis.  These findings are the basis for a patent filing covering various means of generating the ImmCelz® product in a hepatoprotective specific manner. The Company has previously reported that ImmCelz® is capable of treating animal models of stroke,1 as well as inducing “immunological tolerance” in a model of autoimmune rheumatoid arthritis. The work is an extension of previously published findings of Dr. Thomas E. Ichim, in which mesenchymal stem cells were capable of inhibiting progression of liver failure.

Being at the forefront in identifying novel regenerative treatment options, the Company possesses numerous issued patents in the area of cellular therapy, including patent no. 10,842,815 covering use of T regulatory cells for spinal disc regeneration, patent no. 9,598,673 covering stem cell therapy for disc regeneration, patent no. 10,792,310 covering regeneration of ovaries using endothelial progenitor cells and mesenchymal stem cells, patent no. 8,372,797 covering use of stem cells for erectile dysfunction, and patent no. 7,569,385 licensed from the University of California covering a novel stem cell type.

CELZ management including Dr. Ichim, Co-inventor of the patent, and Dr. Amit Patel, Board Member of the Company and Co-Inventor of the Patent Application:

“ImmCelz® is an advancement on our previous liver failure work due to the fact that we have shown transfer of regenerative activity from the stem cell to the immune cell.  Immune cells possess ability to home to injured tissues faster than stem cells due to their smaller size.  Additionally, immune cells possess immunological memory, which we believe may be applied to the concept of regeneration. While stem cell therapeutics are recognized as the future of medicine, I believe it is important to realize that many activities of stem cells are mediated by changes to the immune system. ImmCelz® represents a fundamental advancement in regenerative medicine in that instead of administering stem cells in the body to induce immune modulation, we actually optimize the immune modulation in the laboratory before injecting immune cells into the patient. Liver failure represents a significant unmet medical need and I am extremely excited that ImmCelz® has the potential to help the numerous patients on the liver transplant waiting list who currently have no other option.  With growing validation and acceptance of such technologies, the company intends to continue to broaden its intellectual property portfolio by compiling research data and filing patents, in order to record early filing dates and increase the likelihood of our receiving patent issue. We continue to welcome opportunities with collaborators and Key Opinion Leaders as we are dedicated to accelerating the further development of our technology.”

For More on CELZ Subscribe Right Now

CELZ is making a powerful move up after the Company announced novel data and patent filing No. 63131261 describing the ability of ImmCelz® to reverse liver failure in the carbon tetrachloride preclinical model of hepatocyte necrosis.  These findings are the basis for a patent filing covering various means of generating the ImmCelz® product in a specific manner. CELZ has skyrocketed from well under a penny trading over $10 million in dollar volume today and is quickly attracting legions of new shareholders who see big things happening here. Microcapdaily has reported on CELZ for years stating sometime in 2018: “CELZ has runner in its blood and a long history of huge moves skyrocketing from $0.002 in March of last year to highs topping $0.07 per share in August, CELZ loves to run and is a volume leader regularly among the top most traded on the OTCBB.. CELZ is fully reporting OTCBB with just 601,743,471 shars outstanding and a $2 million market cap; CELZ flagship CaverStem has the only procedure to treat Erectile Dysfunction with adult stem cells in the US. The erectile dysfunction market is booming! According to a recent report from ResearchAndMarkets.com, the size of the global erectile dysfunction market is expected to reach $4.25 billion by 2023. We will be updating on CELZ when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CELZ.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in CELZ either long or short and we have not been compensated for this article.

Ali Raza
A journalist, with experience in web journalism and marketing. Ali holds a master degree in finance and enjoys writing about cryptocurrencies and fintech. Ali’s work has been published on a number of cryptocurrency publications.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.